Tysabri a strong growth driver for Biogen Idec
17 July 2009
Simon Varcoe
Please Login to read the full article.
17 July 2009
Simon Varcoe
simon.varcoe@informa.com
Biogen Idec's second-quarterly revenues increased by 10% to $1.1 billion, driven by strong performances of its multiple sclerosis treatment Avonex (interferon beta-1a) and the controversial MS treatment Tysabri (natalizumab). This is despite Tysabri's continued association with the rare brain infection...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
